Welcome to LookChem.com Sign In|Join Free

CAS

  • or

259263-49-5

Post Buying Request

259263-49-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

259263-49-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 259263-49-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,9,2,6 and 3 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 259263-49:
(8*2)+(7*5)+(6*9)+(5*2)+(4*6)+(3*3)+(2*4)+(1*9)=165
165 % 10 = 5
So 259263-49-5 is a valid CAS Registry Number.

259263-49-5Downstream Products

259263-49-5Relevant articles and documents

Stereochemical reversal of nucleophilic substitution reactions depending upon substituent: Reactions of heteroatom-substituted six-membered-ring oxocarbenium ions through pseudoaxial conformers

Romero, Jan Antoinette C.,Tabacco, Sarah A.,Woerpel

, p. 168 - 169 (2000)

-

Stereoselective synthesis of alicyclic ketones: A hydrogen borrowing approach

Armstrong, Roly J.,Akhtar, Wasim M.,Frost, James R.,Christensen, Kirsten E.,Stevenson, Neil G.,Donohoe, Timothy J.

supporting information, (2019/11/13)

A highly diastereoselective annulation strategy for the synthesis of alicyclic ketones from diols and pentamethylacetophenone is described. This process is mediated by a commercially available iridium(III) catalyst, and provides efficient access to a wide range of cyclopentane and cyclohexane products with high levels of stereoselectivity. The origins of diastereoselectivity in the annulation reaction have been explored by a series of control experiments, which provides an explanation for how each stereocentre around the newly forged ring is controlled.

ETHER COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS

-

Paragraph 0571, (2017/03/14)

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 259263-49-5